ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.

Blood Cancer J · 2017 · PMC5802523 · PMID 29176559

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

approached significanceP = 0.08so close (0.05 < p ≤ 0.1)

However, MDS patients with ASXL1 mutations had a significant increased absolute number of gene mutations (median 2 versus 1, P < 0.0001), which approached significance in the CMML cohort (median 3 versus 2, P = 0.08).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.